New use of low-dose aspirin and risk of colorectal cancer by stage at diagnosis: a nested case-control study in UK general practice

• Published in: BMC cancer Vol. 17; no. 1; p. 637
• Main Authors: García Rodríguez, Luis A, Soriano-Gabarró, Montse, Bromley, Susan, Lanas, Angel, Cea Soriano, Lucía
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 07-09-2017; BioMed Central; BMC
• Subjects: Adult; Aged; Aged, 80 and over; Aspirin; Aspirin - administration & dosage; Aspirin - adverse effects; Care and treatment; Case-Control Studies; Chemoprevention; Clinical medicine; Colonoscopy; Colorectal cancer; Colorectal carcinoma; Colorectal Neoplasms - epidemiology; Colorectal Neoplasms - etiology; Colorectal Neoplasms - pathology; Comorbidity; Diagnosis; Dosage and administration; Female; Health risk assessment; Humans; Identification; Incidence; Life Style; Male; Metastases; Metastasis; Middle Aged; Mortality; Neoplasm Staging; Nested case-control studies; Odds Ratio; Patients; Population; Population Surveillance; Prevention; Primary care; Risk; Risk factors; Task forces; Tumors; United Kingdom - epidemiology; Womens health; United Kingdom; United Kingdom > UK; Aspirin; Diagnosis; Chemoprevention; Nested case-control studies; Colorectal cancer
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-017-3594-9

Evidence from clinical trial populations suggests low-dose aspirin reduces the risk of colorectal cancer (CRC). Part of this reduction in risk might be due to protection against metastatic disease.
We investigated the risk of CRC among new-users of low-dose aspirin (75-300 mg), including risk by stage at diagnosis. Using The Health Improvement Network, we conducted a cohort study with nested case-control analysis. Two cohorts (N = 170,336 each) aged 40-89 years from 2000 to 2009 and free of cancer were identified: i) new-users of low-dose aspirin, ii) non-users of low-dose aspirin, at start of follow-up, matched by age, sex and previous primary care practitioner visits. Patients were followed for up to 12 years to identify incident CRC. 10,000 frequency-matched controls were selected by incidence density sampling where the odds ratio is an unbiased estimator of the incidence rate ratio (RR). RRs with 95% confidence intervals were calculated. Low-dose aspirin use was classified 'as-treated' independent from baseline exposure status to account for changes in exposure during follow-up.
Current users of low-dose aspirin (use on the index date or in the previous 90 days) had a significantly reduced risk of CRC, RR 0.66 (95% CI 0.60-0.74). The reduction in risk was apparent across all age groups, and was unrelated to dose, indication, gender, CRC location or case-fatality status. Reduced risks occurred throughout treatment duration and with all low-dose aspirin doses. RRs by aspirin indication were 0.71 (0·63-0·79) and 0.60 (0.53-0.68) for primary and secondary cardiovascular protection, respectively. Among cases with staging information (n = 1421), RRs for current use of low-dose aspirin were 0.94 (0.66-1.33) for Dukes Stage A CRC, 0.54 (0.42-0.68) for Dukes B, 0.71 (0.56-0.91) for Dukes C, and 0.60 (0.48-0.74) for Dukes D. After 5 years' therapy, the RR for Dukes Stage A CRC was 0.53 (0.24-1.19).
Patients starting low-dose aspirin therapy have a reduced risk of Stages B-D CRC, suggesting a role for low-dose aspirin in the progression of established CRC; a substantial reduction in the risk of Dukes A CRC may occur after 5 years' therapy.